原发性肝癌患者血清胰岛素样生长因子Ⅱ和血管内皮生长因子的检测及意义

目的：探讨原发性肝癌（PHC）患者血清胰岛素样生长因子Ⅱ（IGF-Ⅱ）和血管内皮生长因子（VEGF）的表达及意义。方法：分别采用放射免疫分析法及ELISA法检测63例PHC患者（PHC组）、56例肝硬化患者（肝硬化组1和60例正常对照者（对照组）血清IGF-Ⅱ和VEGF含量，并对PHC患者治疗前后的血清IGF-Ⅱ和VEGF含量进行相关性分析。结果：PHC组患者血清IGF-Ⅱ和VEGF的含量显著高于肝硬化组和对照组（P〈0．05）；肝硬化组血清1GF-Ⅱ和VEGF的含量显著高于对照组（P〈0．05）。经介入治疗后6个月随访，12例复发者血清IGF-Ⅱ和VEGF含量显著高于51侧未复发者（P〈0．05）。治疗前后IGF-Ⅱ与VEGF均呈显著正相关（r=0．43，0．39，P〈0．05）。结论：IGF-Ⅱ与VEGF可作为肿瘤标记物，两者联合检测有助于提高对PHC的检出率，动态检测二者的水平可为临床肝癌的综合治疗及预后判定提供依据。[著者文摘]

Detection and significance of serum IGF-Ⅱ and VEGF in primary hepatocarcinoma patients

[Abstract] Objective To explore the significance and expression of serum insulin like growth factors Ⅱ（IGF-Ⅱ）and vascular endothelial growth factor（VEGF）in primary hepatocarcinoma（PHC）. Methods By using RIA and ELISA, serum IGF-Ⅱ and VEGF levels were determined in 63 patients with PHC, 56 patients with liver cirrhosis and 60 healthy controls. The relationship between IGF-Ⅱ and VEGF were analyzed, before and after treatment. Results The serum IGF-Ⅱ and VEGF levels in PHC group were significantly higher than those in liver cirrhosis group and in healthy control group（P<0.05）. The serum IGF-Ⅱ and VEGF levels in liver cirrhosis group were significantly higher than those in healthy control group（P<0.05）.6 months later after treatment, the serum IGF-Ⅱ and VEGF levels in the patients without recurrence remained normal（P>0.05）. However, the levels in the 12 patients with recurrence returned to those before intervention therapy. Before and after treatment, IGF-Ⅱwere positively correlated in straight line with VEGF（r=0.43,0.39;P<0.05）in PHC. Conclusion Serum IGF-Ⅱ and VEGF can be as tumor marker. The combination detection of serum IGF-Ⅱ and VEGF can improve the detection rates and provide a significant index marker for combined therapy and prognosis in PHC.